AAPL   269.21 (+1.37%)
FB   200.39 (+0.52%)
MSFT   150.68 (+0.50%)
GOOGL   1,339.12 (+1.53%)
AMZN   1,752.57 (-0.46%)
CGC   18.65 (+0.27%)
NVDA   212.04 (+1.25%)
MU   48.09 (+3.15%)
BABA   200.51 (+0.26%)
GE   10.98 (+1.76%)
TSLA   338.28 (+1.58%)
T   38.37 (+0.47%)
AMD   39.94 (+0.63%)
PRI   136.22 (+1.43%)
NFLX   304.56 (+0.08%)
GILD   66.82 (+0.10%)
DIS   147.73 (+0.20%)
AAPL   269.21 (+1.37%)
FB   200.39 (+0.52%)
MSFT   150.68 (+0.50%)
GOOGL   1,339.12 (+1.53%)
AMZN   1,752.57 (-0.46%)
CGC   18.65 (+0.27%)
NVDA   212.04 (+1.25%)
MU   48.09 (+3.15%)
BABA   200.51 (+0.26%)
GE   10.98 (+1.76%)
TSLA   338.28 (+1.58%)
T   38.37 (+0.47%)
AMD   39.94 (+0.63%)
PRI   136.22 (+1.43%)
NFLX   304.56 (+0.08%)
GILD   66.82 (+0.10%)
DIS   147.73 (+0.20%)
AAPL   269.21 (+1.37%)
FB   200.39 (+0.52%)
MSFT   150.68 (+0.50%)
GOOGL   1,339.12 (+1.53%)
AMZN   1,752.57 (-0.46%)
CGC   18.65 (+0.27%)
NVDA   212.04 (+1.25%)
MU   48.09 (+3.15%)
BABA   200.51 (+0.26%)
GE   10.98 (+1.76%)
TSLA   338.28 (+1.58%)
T   38.37 (+0.47%)
AMD   39.94 (+0.63%)
PRI   136.22 (+1.43%)
NFLX   304.56 (+0.08%)
GILD   66.82 (+0.10%)
DIS   147.73 (+0.20%)
AAPL   269.21 (+1.37%)
FB   200.39 (+0.52%)
MSFT   150.68 (+0.50%)
GOOGL   1,339.12 (+1.53%)
AMZN   1,752.57 (-0.46%)
CGC   18.65 (+0.27%)
NVDA   212.04 (+1.25%)
MU   48.09 (+3.15%)
BABA   200.51 (+0.26%)
GE   10.98 (+1.76%)
TSLA   338.28 (+1.58%)
T   38.37 (+0.47%)
AMD   39.94 (+0.63%)
PRI   136.22 (+1.43%)
NFLX   304.56 (+0.08%)
GILD   66.82 (+0.10%)
DIS   147.73 (+0.20%)
Log in

NYSE:HUM - Humana Stock Price, Forecast & News

$349.26
+4.05 (+1.17 %)
(As of 12/6/2019 10:12 AM ET)
Today's Range
$346.44
Now: $349.26
$349.26
50-Day Range
$275.11
MA: $315.09
$346.00
52-Week Range
$225.65
Now: $349.26
$346.80
Volume4,314 shs
Average Volume1.20 million shs
Market Capitalization$46.25 billion
P/E Ratio24.00
Dividend Yield0.64%
Beta0.9
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. Read More…

Industry, Sector and Symbol

Industry Hospital & medical service plans
Sub-IndustryManaged Health Care
SectorMedical
CUSIP44485910
Phone502-580-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$56.91 billion
Cash Flow$19.23 per share
Book Value$74.95 per share

Profitability

Net Income$1.68 billion

Miscellaneous

Employees41,600
Market Cap$46.25 billion
Next Earnings Date2/5/2020 (Estimated)
OptionableOptionable

Receive HUM News and Ratings via Email

Sign-up to receive the latest news and ratings for HUM and its competitors with MarketBeat's FREE daily newsletter.


Humana (NYSE:HUM) Frequently Asked Questions

What is Humana's stock symbol?

Humana trades on the New York Stock Exchange (NYSE) under the ticker symbol "HUM."

How often does Humana pay dividends? What is the dividend yield for Humana?

Humana announced a quarterly dividend on Thursday, October 24th. Shareholders of record on Tuesday, December 31st will be paid a dividend of $0.55 per share on Friday, January 31st. This represents a $2.20 dividend on an annualized basis and a yield of 0.63%. The ex-dividend date of this dividend is Monday, December 30th. View Humana's Dividend History.

How will Humana's stock buyback program work?

Humana declared that its board has initiated a stock buyback program on Friday, December 15th 2017, which permits the company to buyback $3,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to purchase shares of its stock through open market purchases. Shares buyback programs are generally an indication that the company's board believes its shares are undervalued.

How were Humana's earnings last quarter?

Humana Inc (NYSE:HUM) announced its earnings results on Wednesday, November, 6th. The insurance provider reported $5.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.58 by $0.45. The insurance provider earned $16.24 billion during the quarter, compared to the consensus estimate of $16.15 billion. Humana had a net margin of 4.06% and a return on equity of 22.32%. Humana's revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter last year, the company posted $4.58 earnings per share. View Humana's Earnings History.

When is Humana's next earnings date?

Humana is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for Humana.

What guidance has Humana issued on next quarter's earnings?

Humana issued an update on its FY 2019 After-Hours earnings guidance on Monday, December, 2nd. The company provided EPS guidance of 17.75-17.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $17.77.

What price target have analysts set for HUM?

16 Wall Street analysts have issued twelve-month price targets for Humana's shares. Their forecasts range from $275.02 to $370.00. On average, they expect Humana's share price to reach $326.00 in the next year. This suggests that the stock has a possible downside of 6.7%. View Analyst Price Targets for Humana.

What is the consensus analysts' recommendation for Humana?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Humana in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Humana.

What are Wall Street analysts saying about Humana stock?

Here are some recent quotes from research analysts about Humana stock:
  • 1. According to Zacks Investment Research, "Humana’s shares have lost year-to-date against its industry’s gain. Moreover, the company has witnessed its 2020 earnings estimates move south over the last 30 days. Its rising level of expenses since 2010 persistently weighs on the bottom line. The company expects high benefit expenses which will lead to an overall increase in operating expenses going forward. Also, increase in leverage might lead to heightened financial risk for the company and burden on margins. Nevertheless, it is well-poised for growth on the back of its strong Medicare business. Its top line has been witnessing an uptrend for the past several years. Acquisitions and dispositions made by the company have also led to business growth over the last few quarters." (4/11/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We reiterate our Neutral rating on HUM shares and maintain our 12-month price target of $325. After the market close on the company reaffirmed its 2018 EPS guidance. The company also provided updated 2019 membership metrics. Given the update, we are increasing our 2019 revenue and EPS estimates. The company had previously indicated that it expected 2019 adjusted EPS to grow above its stated long-term goal of 11-15%. With its filing on Wednesday, the company did not comment on 2019 EPS guidance, but will provide detailed 2019 financial guidance when it reports 4Q18 and year-end 2018 results on Wednesday, February 6, 2019." (1/2/2019)

Has Humana been receiving favorable news coverage?

News coverage about HUM stock has been trending somewhat negative this week, InfoTrie reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Humana earned a news impact score of -1.0 on InfoTrie's scale. They also gave news stories about the insurance provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Humana.

Are investors shorting Humana?

Humana saw a increase in short interest in November. As of November 15th, there was short interest totalling 2,420,000 shares, an increase of 26.0% from the October 31st total of 1,920,000 shares. Based on an average daily volume of 1,000,000 shares, the days-to-cover ratio is currently 2.4 days. Approximately 1.8% of the shares of the stock are sold short. View Humana's Current Options Chain.

Who are some of Humana's key competitors?

What other stocks do shareholders of Humana own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Humana investors own include UnitedHealth Group (unh), Boeing (BA), NVIDIA (NVDA), Mastercard (MA), Visa (V), Alibaba Group (BABA), Walt Disney (DIS), JPMorgan Chase & Co. (JPM), Amgen (AMGN) and Cigna (CI).

Who are Humana's key executives?

Humana's management team includes the folowing people:
  • Mr. Bruce Dale Broussard, Pres, CEO & Director (Age 57)
  • Mr. Brian Andrew Kane, Chief Financial Officer (Age 46)
  • Mr. Timothy S. Huval, Chief HR Officer (Age 53)
  • Ms. Jody L. Bilney, Chief Consumer Officer (Age 58)
  • Dr. William Kevin Fleming Pharm.D., PharmD, RPh, Segment Pres of Healthcare Services (Age 51)

Who are Humana's major shareholders?

Humana's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (4.40%), Newport Trust Co (1.26%), Boston Partners (1.03%), Maverick Capital Ltd. (0.65%), California Public Employees Retirement System (0.63%) and Diamond Hill Capital Management Inc. (0.55%). Company insiders that own Humana stock include Brian P Leclaire, Bruce D Broussard, Christopher H Hunter, Cynthia H Zipperle, David A Jr/Ky Jones, Elizabeth D Bierbower, Heidi S Margulis, James J /Ky Obrien, Jody L Bilney, M Todoroff Christopher, Roy A Beveridge, Timothy Alan Wheatley, Timothy S Huval and William Kevin Fleming. View Institutional Ownership Trends for Humana.

Which major investors are selling Humana stock?

HUM stock was sold by a variety of institutional investors in the last quarter, including Maverick Capital Ltd., PointState Capital LP, Point72 Asset Management L.P., Russell Investments Group Ltd., Man Group plc, State Street Corp, Rhenman & Partners Asset Management AB and Scout Investments Inc.. Company insiders that have sold Humana company stock in the last year include Brian P Leclaire, Christopher H Hunter, Heidi S Margulis, James J /Ky Obrien, Roy A Beveridge and Timothy Alan Wheatley. View Insider Buying and Selling for Humana.

Which major investors are buying Humana stock?

HUM stock was purchased by a variety of institutional investors in the last quarter, including Boston Partners, Voya Investment Management LLC, Diamond Hill Capital Management Inc., Orbimed Advisors LLC, Ardevora Asset Management LLP, Artemis Investment Management LLP, Vantage Investment Partners LLC and York Capital Management Global Advisors LLC. View Insider Buying and Selling for Humana.

How do I buy shares of Humana?

Shares of HUM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Humana's stock price today?

One share of HUM stock can currently be purchased for approximately $349.26.

How big of a company is Humana?

Humana has a market capitalization of $46.25 billion and generates $56.91 billion in revenue each year. The insurance provider earns $1.68 billion in net income (profit) each year or $14.55 on an earnings per share basis. Humana employs 41,600 workers across the globe.View Additional Information About Humana.

What is Humana's official website?

The official website for Humana is http://www.humana.com/.

How can I contact Humana?

Humana's mailing address is 500 West Main Street, LOUISVILLE KY, 40202. The insurance provider can be reached via phone at 502-580-1000 or via email at [email protected]


MarketBeat Community Rating for Humana (NYSE HUM)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  751 (Vote Outperform)
Underperform Votes:  796 (Vote Underperform)
Total Votes:  1,547
MarketBeat's community ratings are surveys of what our community members think about Humana and other stocks. Vote "Outperform" if you believe HUM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HUM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel